Dr. James Yarger, Ph.D., Chief Executive Officer
Dr. James Yarger is an accomplished scientist and executive with extensive scientific, management, and operational experience. His expertise is in molecular biology, regulatory affairs, API manufacturing and business. He has more than 30 years of metabolic engineering and success in the pharmaceutical drug discovery and development business.
In 2006 Dr. Yarger founded ENDECE. Dr. Yarger is responsible for ENDECE’s scientific and business strategies and corporate development including fund raising and building the respected ENDECE network.
Prior to ENDECE, Dr. Yarger co-founded Cedarburg Pharmaceuticals. As President and CEO he was responsible for the scientific strategy, business development, FDA and DEA compliance and audits (including FDA inspections) that led to the company’s growth. He raised equity capital (over $15 million) and designed and built the Cedarburg Pharmaceutical research and manufacturing facility.
Dr. Yarger’s previous experience also includes the team effort to develop and commercialize the genetically engineered drug, Aprotinin, for Miles Laboratories, Inc. (Bayer, AG).
In addition, while with Amoco BioProducts Corporation, Dr. Yarger was part of the team responsible for the synthesis of vitamin D analogs and carotenoids through metabolic engineering. This work led to the patenting and commercialization of a vitamin D analog, 25-hydroxy vitamin D3 (Hy-D.). While at Amoco BioProducts, he was also responsible for regulatory affairs and wrote and filed a GRAS petition with the FDA approval.
Dr. Yarger holds a PhD in Molecular Biology from Brandeis University and was a Post-doctoral Fellow at Harvard. He is author of 12 scientific publications, 22 published scientific abstracts, and holds 14 awarded or filed patents.
